Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

25.00p
   
  • Change Today:
    -1.80p
  • 52 Week High: 212.60
  • 52 Week Low: 18.46
  • Currency: UK Pounds
  • Shares Issued: 201.37m
  • Volume: 153,127
  • Market Cap: £50.34m
  • RiskGrade: 510

Synairgen Overview

In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory viruses can cause serious illness, with the aim of translating these insights into effective clinical treatments. Joined by fellow University of Southampton professors Donna Davies and Ratko Djukanovic in the 1990s, together the three formed Synairgen in 2003 with the sole aim of bringing these advances to patients.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 1.4  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Synairgen Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 5.03 1.63 1.92p 5.6 n/a n/a n/a 0.0%
31-Dec-18 0.10 (4.10) (3.45)p n/a n/a n/a n/a 0.0%
31-Dec-19 n/a (4.79) (3.53)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (17.73) (9.46)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (57.86) (24.28)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Synairgen Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 n/a (25.70) (11.80)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a n/a n/a n/a n/a n/a n/a 0.0%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

Synairgen Company Announcements

Grant of Options 06-Jul-2022 07:00 RNS
Result of AGM 30-Jun-2022 13:45 RNS
Second Price Monitoring Extn 23-Jun-2022 16:40 RNS

Synairgen ShareCast News

Synairgen posts positive clinical trial data for... 16-May-2022 ShareCast
Synairgen falls as patient recruitment halted on... 17-Mar-2022 ShareCast
Synairgen asked to pause activities on Covid-19 ... 03-Mar-2022 ShareCast

Synairgen Top Newspaper Links

AstraZeneca buys the rights to an asthma treatme... 13-Jun-2014 Daily Mail
AstraZeneca in new £138million asthma drug deal 13-Jun-2014 Express & Star

Latest Synairgen Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Synairgen Market Data

Currency UK Pounds
Share Price 25.00p
Change Today -1.80p
% Change -6.72 %
52 Week High 212.60
52 Week Low 18.46
Volume 153,127
Shares Issued 201.37m
Market Cap £50.34m
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.24% above the market average27.24% above the market average27.24% above the market average27.24% above the market average27.24% above the market average
53.57% above the sector average53.57% above the sector average53.57% above the sector average53.57% above the sector average53.57% above the sector average
Price Trend
98.52% below the market average98.52% below the market average98.52% below the market average98.52% below the market average98.52% below the market average
96.88% below the sector average96.88% below the sector average96.88% below the sector average96.88% below the sector average96.88% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 11-Aug-2022

Time Volume / Share Price
16:48 2,773 @ 25.21p
16:35 2,770 @ 25.00p
16:29 1,438 @ 25.80p
16:29 1,762 @ 27.00p
16:29 200 @ 26.76p

Synairgen Key Personnel

CEO Richard J Marsden
Finance Director John C Ward

Top of Page